Compare Incyte Corporation (INCY) vs Nucor Corporation (NUE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Nucor Corporation — how do they compare? Incyte Corporation trades at $117.9 (market cap $23.11B), while Nucor Corporation trades at $235.56 (market cap $52.55B). The key difference: Nucor Corporation is far larger — about 2.3× Incyte Corporation's market cap, and Nucor Corporation pays a 0.97% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | NUE | |
|---|---|---|
Market Cap | $23.11B | $52.55B |
Sector | Health | Basic Materials |
52-Week High | $118.52 | $266.35 |
52-Week Low | $67.38 | $131.78 |
Enterprise Value | $19.13B | $57.19B |
Dividend Yield | — | 0.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Nucor (NUE) trades at $231.86, down 2.01% today, with a bullish technical signal from moving averages and a consensus analyst price target of $263.11. Recent earnings beat expectations in Q1 2026 with EPS of $3.23 versus $2.82 forecast, though Q4 2025 missed. Revenue trends show recovery from $30.7B in 2024 to $32.5B in 2025, with net income margin improving to 6.82% in 2026 projections. The company maintains a strong balance sheet with a debt-to-asset ratio of 20.23% in 2025 and recently announced a joint venture to support AI power infrastructure.
Outlook remains positive driven by higher steel prices and strategic expansions, but risks include cyclical demand weakness and volatile cash flows. Analyst sentiment is bullish with 62.5% buy ratings, supporting potential upside from current levels, though investors should monitor execution on Q2 2026 earnings expected at $4.45 EPS.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →
